ClinicalTrials.gov
public full text
Public Domain
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Complement Activation in Primary IgA Nephropathy (CAIGAN): study protocol for an international prospective multicenter observational cohort study#1157751
- Breaking tolerance in the glomerulus: complement as a driver and therapeutic target in IgA nephropathy.#465200
- High complement activation index predicts renal progression in crescentic IgA nephropathy.#1134589
- An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL#876683
- A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis#879383
Record · ID 853576
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive